

## Supplementary Material

Supplement to: Binkhorst M, Offringa AK, Van der Hoeven JG. COVID-19: comprehensive synopsis of suggested pathophysiological mechanisms and repurposed drugs.

Corresponding author: Mathijs Binkhorst, Department of Neonatology, Amalia Children's Hospital, Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands.

E-mail: mathijs.binkhorst@radboudumc.nl.

The references listed below were all used to gather information for the composition of the pathophysiological overview presented in the abovementioned paper.

### Published papers

- 1 Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. *Allergy* 2007; **62**: 842–56. <https://doi.org/10.1111/j.1398-9995.2007.01427.x>.
- 2 Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMcp2009575>.
- 3 Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? *Circulation* 2020. <https://doi.org/10.1161/CIRCULATIONAHA.120.047419>.
- 4 Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. *Lancet* 2020; **395**: 1545–46. [https://doi.org/10.1016/S0140-6736\(20\)31025-4](https://doi.org/10.1016/S0140-6736(20)31025-4).

- 5 da Silva RL. Viral-associated thrombotic microangiopathies. *Hematol Oncol Stem Cell Ther* 2011; **4**: 51–59. <https://doi.org/10.5144/1658-3876.2011.51>.
- 6 Danis VA, Rathjen DA, Brooks PM. The effect of slow acting antirheumatic drugs on the production of cytokines by human monocytes. *Inflammopharmacology* 1992; **1**: 315–27. <https://doi.org/10.1007/BF02755882>.
- 7 Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet* 2020; **395**: 1407–09. [https://doi.org/10.1016/S0140-6736\(20\)30858-8](https://doi.org/10.1016/S0140-6736(20)30858-8).
- 8 Gao J, Hu S. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). *Biosci Trends* 2020; **14**: 156–58. <https://doi.org/10.5582/bst.2020.03072>.
- 9 Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* 2020; **14**: 72–73. <https://doi.org/10.5582/bst.2020.01047>.
- 10 Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients* 2020; **12**. <https://doi.org/10.3390/nu12040988>.
- 11 Gul MH, Htun ZM, Shaukat N, Imran M, Khan A. Potential specific therapies in COVID-19. *Ther Adv Respir Dis* 2020; **14**: 1-12. <https://doi.org/10.1177/1753466620926853>.
- 12 Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004; **203**: 631–37. <https://doi.org/10.1002/path.1570>.
- 13 Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pöhlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments

- entry driven by the severe acute respiratory syndrome coronavirus spike protein. *J Virol* 2014; **88**: 1293–307. <https://doi.org/10.1128/JVI.02202-13>.
- 14 Hoffmann M, Kleine-Weber H, Pöhlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. *Mol Cell* 2020; **78**: 779–84.e5. <https://doi.org/10.1016/j.molcel.2020.04.022>.
- 15 Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* 2020; **181**: 271–80.e8. <https://doi.org/10.1016/j.cell.2020.02.052>.
- 16 Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. *J Intensive Care* 2020; **8**: 36. <https://doi.org/10.1186/s40560-020-00453-4>.
- 17 Iikuni N, Lam QLK, Lu L, Matarese G, La Cava A. Leptin and inflammation. *Curr Immunol Rev* 2008; **4**: 70–79. <https://doi.org/10.2174/157339508784325046>.
- 18 Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. *Lancet Respir Med* 2020. [https://doi.org/10.1016/S2213-2600\(20\)30226-5](https://doi.org/10.1016/S2213-2600(20)30226-5).
- 19 Ito T. PAMPs and DAMPs as triggers for DIC. *J Intensive Care* 2014; **2**: 67. <https://doi.org/10.1186/s40560-014-0065-0>.
- 20 Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino RB, Harrington DP. Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMe2012924>.
- 21 Johnston DT. Diagnosis and management of hereditary angioedema. *The Journal of the American Osteopathic Association* 2011; **111**: 28–36.
- 22 Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. *Lancet Respir Med* 2020. [https://doi.org/10.1016/S2213-2600\(20\)30216-2](https://doi.org/10.1016/S2213-2600(20)30216-2).

- 23 King A, Vail A, O'Leary C, et al. Anakinra in COVID-19: important considerations for clinical trials. *Lancet Rheumatol* 2020. [https://doi.org/10.1016/S2665-9913\(20\)30160-0](https://doi.org/10.1016/S2665-9913(20)30160-0).
- 24 Kuhr F, Lowry J, Zhang Y, Brovkovich V, Skidgel RA. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. *Neuropeptides* 2010; **44**: 145–54. <https://doi.org/10.1016/j.npep.2009.12.004>.
- 25 Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. *Lancet Haematology* 2020; **7**: e438-e440. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9).
- 26 Li H, Liu L, Zhang D, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. *Lancet* 2020; **395**: 1517–20. [https://doi.org/10.1016/S0140-6736\(20\)30920-X](https://doi.org/10.1016/S0140-6736(20)30920-X).
- 27 Li L, Li R, Wu Z, et al. Therapeutic strategies for critically ill patients with COVID-19. *Ann Intensive Care* 2020; **10**: 45. <https://doi.org/10.1186/s13613-020-00661-z>.
- 28 Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. *Infect Dis Poverty* 2020; **9**: 45. <https://doi.org/10.1186/s40249-020-00662-x>.
- 29 Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. *J Thromb Haemost* 2020; **18**: 786–87. <https://doi.org/10.1111/jth.14781>.
- 30 Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 2020; **6**: 16. <https://doi.org/10.1038/s41421-020-0156-0>.
- 31 Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. *Circulation* 2020. <https://doi.org/10.1161/CIRCULATIONAHA.120.047549>.
- 32 Liu T, Zhang L, Joo D, Sun S-C. NF- $\kappa$ B signaling in inflammation. *Signal Transduct Target Ther* 2017; **2**. <https://doi.org/10.1038/sigtrans.2017.23>.

- 33 Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. *N Engl J Med* 2020.  
<https://doi.org/10.1056/NEJMoa2006923>.
- 34 McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. *Lancet Rheumatol* 2020.  
[https://doi.org/10.1016/S2665-9913\(20\)30121-1](https://doi.org/10.1016/S2665-9913(20)30121-1).
- 35 Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. *Lancet* 2020. [https://doi.org/10.1016/s0140-6736\(20\)31180-6](https://doi.org/10.1016/s0140-6736(20)31180-6).
- 36 Nayer A, Ortega LM. Catastrophic antiphospholipid syndrome: a clinical review. *J Nephropathol* 2014; **3**: 9–17. <https://doi.org/10.12860/jnp.2014.03>.
- 37 Offringa A, Montijn R, Singh S, Paul M, Pinto YM, Pinto-Sietsma S-J. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system. *Eur Heart J Cardiovasc Pharmacother* 2020. <https://doi.org/10.1093/ehjcvp/pvaa053>.
- 38 O'Neill LAJ, Netea MG. BCG-induced trained immunity: can it offer protection against COVID-19? *Nat Rev Immunol* 2020. <https://doi.org/10.1038/s41577-020-0337-y>.
- 39 Oxley TJ, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. *N Engl J Med* 2020; **382**: e60. <https://doi.org/10.1056/NEJMc2009787>.
- 40 Relan A, Bakhtiari K, van Amersfoort ES, Meijers JCM, Hack CE. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema. *BioDrugs* 2012; **26**: 43–52. <https://doi.org/10.2165/11599490-000000000-00000>.
- 41 Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. *N Engl J Med* 2020.  
<https://doi.org/10.1056/NEJMoa2008975>.

- 42 Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet* 2020; **395**: e30-e31. [https://doi.org/10.1016/S0140-6736\(20\)30304-4](https://doi.org/10.1016/S0140-6736(20)30304-4).
- 43 Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? *Nat Rev Immunol* 2020. <https://doi.org/10.1038/s41577-020-0320-7>.
- 44 Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ. Characterization of ACE and ACE2 expression within different organs of the NOD mouse. *Int J Mol Sci* 2017; **18**. <https://doi.org/10.3390/ijms18030563>.
- 45 Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol* 2020; **16**: 155–66. <https://doi.org/10.1038/s41584-020-0372-x>.
- 46 Seif F, Aazami H, Khoshmirsafa M, et al. JAK inhibition as a new treatment strategy for patients with COVID-19. *Int Arch Allergy Immunol* 2020: 1–9. <https://doi.org/10.1159/000508247>.
- 47 Sproston NR, Ashworth JJ. Role of c-reactive protein at sites of inflammation and infection. *Front Immunol* 2018; **9**: 754. <https://doi.org/10.3389/fimmu.2018.00754>.
- 48 Stawicki S, Jeanmonod R, Miller A, et al. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2) pandemic: a joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 working group consensus paper. *J Global Infect Dis* 2020; **12**: 47. [https://doi.org/10.4103/jgid.jgid\\_86\\_20](https://doi.org/10.4103/jgid.jgid_86_20).
- 49 Tolouian R, Zununi Vahed S, Ghiyasvand S, Tolouian A, Ardalan M. COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. *J Renal Inj Prev* 2020; **9**: e19-e19. <https://doi.org/10.34172/jrip.2020.19>.

- 50 Upreti H, Kasmani J, Dane K, et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. *Blood* 2019; **134**: 1037–45.  
<https://doi.org/10.1182/blood.2019001056>.
- 51 van de Veerdonk FL, Netea MG, van Deuren M, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. *Elife* 2020; **9**.  
<https://doi.org/10.7554/eLife.57555>.
- 52 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 2020; **395**: 1417–18. [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5).
- 53 Wang X, Xu W, Hu G, et al. SARS-CoV-2 infects t lymphocytes through its spike protein-mediated membrane fusion. *Cell Mol Immunol* 2020.  
<https://doi.org/10.1038/s41423-020-0424-9>.
- 54 Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**: 1569–78. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9).
- 55 Williams B, Zhang Y. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. *Lancet* 2020; **395**: 1671–73. [https://doi.org/10.1016/S0140-6736\(20\)31131-4](https://doi.org/10.1016/S0140-6736(20)31131-4).
- 56 Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. *Lupus* 2006; **15**: 268–75. <https://doi.org/10.1191/0961203306lu2299oa>.
- 57 Zhang Y, Gao Y, Qiao L, Wang W, Chen D. Inflammatory response cells during acute respiratory distress syndrome in patients with coronavirus disease 2019 (COVID-19). *Ann Intern Med* 2020. <https://doi.org/10.7326/L20-0227>.

- 58 Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. *N Engl J Med* 2020; **382**: e38.  
<https://doi.org/10.1056/NEJMc2007575>.
- 59 Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. *Annu Rev Med* 2015; **66**: 211–25. <https://doi.org/10.1146/annurev-med-061813-013241>.
- 60 Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. *Front Immunol* 2018; **9**: 302. <https://doi.org/10.3389/fimmu.2018.00302>.

#### **Accepted papers**

- 61 Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy* 2020.  
<https://doi.org/10.1111/all.14364>.
- 62 Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and pathophysiology of coronavirus disease 2019 (COVID-19). *J Pathol* 2020. <https://doi.org/10.1002/path.5471>.
- 63 Guoping L, Xiang H, Zhang L, et al. Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. *J Autoimmun* 2020.  
<https://doi.org/10.1016/j.jaut.2020.102463>.
- 64 Hastie CE, Mackay DF, Ho F, et al. Vitamin D concentrations and COVID-19 infection in UK Biobank. *Diabetes Metab Syndr* 2020; **14**: 561-565.
- 65 Hoffmann M, Schroeder S, Kleine-Weber H, et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. *Antimicrob Agents Chemother* 2020. <https://doi.org/10.1128/AAC.00754-20>.

- 66 Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res* 2020. <https://doi.org/10.1007/s40520-020-01570-8>.
- 67 Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. *Lancet Infect Dis* 2020. [https://doi.org/10.1016/S1473-3099\(20\)30296-6](https://doi.org/10.1016/S1473-3099(20)30296-6).
- 68 Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020. <https://doi.org/10.1093/cid/ciaa237>.

### **Journal pre-proof papers**

- 69 Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; a narrative review for emergency providers. *Am J Emerg Med* 2020. <https://doi.org/10.1016/j.ajem.2020.04.035>.
- 70 Oudkerk M, Büller HR, Kuijpers D, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. *Radiology* 2020. <https://doi.org/10.1148/radiol.2020201629>.

### **Preprints from medRxiv and bioRxiv**

- 71 Abdulhak AAB, Kashour T, Noman A, et al. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and outcome of COVID-19: a systematic review and meta-analysis. *MedRxiv* 2020. <https://doi.org/10.1101/2020.05.06.20093260>.
- 72 Azouz NP, Klingler AM, Rothenberg ME. Alpha 1 antitrypsin is an inhibitor of the SARS-CoV2-priming protease TMPRSS2. *BioRxiv* 2020. <https://doi.org/10.1101/2020.05.04.077826>.

- 73 Bian H, Zheng ZH, Wei D, et al. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. *MedRxiv* 2020.  
<https://doi.org/10.1101/2020.03.21.20040691>.
- 74 Chen, Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *MedRxiv* 2020.  
<https://doi.org/10.1101/2020.03.22.20040758>.
- 75 Chroboczek T, Lacoste M, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. *MedRxiv* 2020.  
<https://doi.org/10.1101/2020.05.08.20094755>.
- 76 Davies G, Garami AR, Byers JC. Evidence Supports a Causal Model for Vitamin D in COVID-19 Outcomes. *MedRxiv* 2020. <https://doi.org/10.1101/2020.05.01.20087965>.
- 77 De Smet D, De Smet K, Herroelen P, Gryspeerd S, Martens GA. Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics. *MedRxiv* 2020.  
<https://doi.org/10.1101/2020.05.01.20079376>.
- 78 Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Van der Heide RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. *MedRxiv* 2020.  
<https://doi.org/10.1101/2020.04.06.20050575>.
- 79 Goyal A, Cardozo-Ojeda EF, Schiffer JT. Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.10.20061325>.
- 80 Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin converting enzyme inhibitors or angiotensin receptor blockers. *MedRxiv* 2020.  
<https://doi.org/10.1101/2020.04.29.20085787>.

- 81 Hornuss D, Lange B, Schroeter N, Rieg S, Kern WV, Wagner D. Anosmia in COVID-19 patients. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.28.20083311>.
- 82 Kapoor KM, Kapoor A. Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review. *MedRxiv* 2020. <https://doi.org/10.1101/2020.03.24.20042366>.
- 83 Lane JCE, Weaver J, Kostka K, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.08.20054551>.
- 84 Liu N, Hong Y, Chen RG, Zhu HM. High rate of increased level of plasma Angiotensin II and its gender difference in COVID-19: an analysis of 55 hospitalized patients with COVID-19 in a single hospital, WuHan, China. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.27.20080432>.
- 85 Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.16.20065920>.
- 86 Mahevas M, Tran VT, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.10.20060699>.
- 87 Mycroft-West C, Su D, Li Y, et al. SARS-CoV-2 Spike S1 receptor binding domain undergoes conformational change upon interaction with low molecular weight heparins. *BioRxiv* 2020. <https://doi.org/10.1101/2020.04.29.068486>.

- 88 Parma V, Ohla K, Veldhuizen MG, et al. More than just smell-COVID-19 is associated with severe impairment of smell, taste, and chemesthesis. *MedRxiv* 2020. <https://doi.org/10.1101/2020.05.04.20090902>.
- 89 Pinto BG, Oliveira AE, Singh Y, et al. ACE2 Expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. *MedRxiv* 2020. <https://doi.org/10.1101/2020.03.21.20040261>.
- 90 Previtali G, Seghezzi M, Muioli V, et al. The pathogenesis of thromboembolic disease in COVID-19 patients: could be a catastrophic antiphospholipid syndrome? *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.30.20086397>
- 91 Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 patients with convalescent plasma in Houston, Texas. *MedRxiv* 2020. <https://doi.org/10.1101/2020.05.08.20095471>.
- 92 Smeitink J, Jiang X, Pecheritsyna S, Renkema H, van Maanen R, Beyrath J. Hypothesis: mPGES-1- derived prostaglandin E2, a so far missing link in COVID-19 pathophysiology? *Preprints* 2020. <https://doi.org/10.20944/preprints202004.0180.v1>.
- 93 Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.10.20060558>.
- 94 Van de Veerdonk FL, Janssen NAF, Grondman I, et al. A systems approach to inflammation identifies therapeutic targets in SARS-cov-2 infection. *MedRxiv* 2020. <https://doi.org/10.1101/2020.05.23.20110916>.
- 95 Van der Voort P, Moser J, Zandstra DF, et al. A clinical and biological framework on the role of visceral fat tissue and leptin in SARS-CoV-2 infection related respiratory failure. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.30.20086108>.

- 96 Yamamoto M, Kiso M, Sakai-TagawaY, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection *in vitro*: an existing drug with multiple possible effects. *BioRxiv* 2020: <https://doi.org/10.1101/2020.04.22.054981>.
- 97 Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. *MedRxiv* 2020. <https://doi.org/10.1101/2020.04.27.20073379>.

### Websites

- 98 Caforio AL. COVID-19 and myocarditis. Fifth Webinar: ‘COVID-19, cardiomyopathies and myocarditis - ERN GUARD HEART’ May 7th, 2020. [https://ec.europa.eu/health/sites/health/files/ern/docs/ev\\_20200507\\_co03\\_en.pdf](https://ec.europa.eu/health/sites/health/files/ern/docs/ev_20200507_co03_en.pdf). (accessed on May 27, 2020).
- 99 National Center for Biotechnology Information. PubChem Database. Nafamostat mesylate, CID=5311180, <https://pubchem.ncbi.nlm.nih.gov/compound/Nafamostat-mesylate> (accessed on May 27, 2020).
- 100Vollaard A, Gieling E, Van der Linden P, Sinha B, de Boer M. Pharmacological treatment options for hospitalised patients with COVID-19. Dutch Working Party on Antibiotic Policy (Dutch: SWAB), version May 1, 2020. <https://swab.nl/nl/COVID-19> [Dutch]. (accessed on May 27, 2020).